NIRV Stock Overview
Engages in the scientific research and development of therapeutic products derived from psychedelics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Nirvana Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.01 |
| Beta | -1.21 |
| 11 Month Change | -75.00% |
| 3 Month Change | -80.00% |
| 1 Year Change | -71.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| NIRV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -33.3% | 5.6% | 1.1% |
| 1Y | -71.4% | 39.7% | 9.9% |
Return vs Industry: NIRV underperformed the Canadian Pharmaceuticals industry which returned 39.3% over the past year.
Return vs Market: NIRV underperformed the Canadian Market which returned 11.3% over the past year.
Price Volatility
| NIRV volatility | |
|---|---|
| NIRV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.9% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: NIRV's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NIRV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Bruce Clark | nirvanalifescience.com |
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. It also focuses on developing methodologies for extraction and purification of psychoactive compounds. The company is headquartered in Vancouver, Canada.
Nirvana Life Sciences Inc. Fundamentals Summary
| NIRV fundamental statistics | |
|---|---|
| Market cap | CA$482.33k |
| Earnings (TTM) | -CA$1.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs NIRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NIRV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.23m |
| Earnings | -CA$1.23m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -2.9% |
How did NIRV perform over the long term?
See historical performance and comparison